Broker target at 230p
Come back this afternoon and see SP will be up 200%+
Last week. the Centers for Medicare and Medicaid Services has published a draft local coverage determination for Renalytix for KidneyIntelX and kidneyintelIX.dkd. The Medicare price is $950/test. The specified coverage is for patients with diagnosed Tupe 2 diabetes and Stage 1-3b Chronic Kidney Disease.
Renalytix is participating in the BTIG MedTech conference in Utah on 13-14 February.
Kidney disease affects more than 850 million people around the world and 38 million people in the US have chronic kidney disease. Around 35 million US people have Type 2 diabetes.
A study of KidneyIntelX at a major US clinical centre. After one year, blood pressure control improved as did blood glucose control. The rate of kidney function decline reduced across all risk categories.
Remember to bank a little along the way and you'll be more happier
Get lost call centre lady.
Clearly someone hurry to load up.
Predator7, I'm good thank ππ
Everyone can make money here, some people just mooning for sake of it and give advise others without investing.
Davey50, what a tosspot. Do you even know how the stock market works? You've just been sitting on the side-lines since yesterday, mooning around like an old clown, while expert investors are making money.
Thank you! i have taken profits. Good luck all.
2 trade today π₯π₯π₯ what a start π
Held this π© for 8 years π
What a π€‘ his phone order never got filled for years while everyone was dumping πΏ
Davey50 Is broke π€‘ biggest liar here π heβs full of π©π©
P&d stock by old school phone in to trade π
This is going to drop hard tomorrow π
Some amateurs donβt understand whatβs happening here. Big boys taking over π°π°π°π°
Heavily shortened π
π€‘ get back to school tomorrow π
π€‘ keep talking to yourself π
No one care what you do π let the big boys buy and make money π
Nano-cap HealthTech Renalytix (NASDAQ:RNLX) surged more than 500% on Monday after the company announced a draft Medicare policy that, if finalized, will establish coverage for its diagnostic platform, KidneyIntelX, and its testing service, KidneyIntelX.dkd.
The so-called Local Coverage Determination (βLCDβ) has indicated pricing for KidneyIntelX and kidneyintelX at $950 per test, according to the New York-based company.